imatinib mesylate and Granulocytic Leukemia
imatinib mesylate has been researched along with Granulocytic Leukemia in 89 studies
Research
Studies (89)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (2.25) | 18.2507 |
2000's | 50 (56.18) | 29.6817 |
2010's | 24 (26.97) | 24.3611 |
2020's | 13 (14.61) | 2.80 |
Authors
Authors | Studies |
---|---|
Adachi, K; Araki, M; Asada, S; Fukushima, T; Fukuyama, T; Goyama, S; Imai, M; Ito, R; Kitamura, T; Komatsu, N; Lamagna, C; Masuda, ES; Mikami, K; Morishita, S; Nagata, M; Takaku, T; Takeda, R; Takizawa, H; Tamura, M; Tanaka, Y; Tsuchiya, S; Umemoto, T; Watanabe, N | 1 |
Beg, MMA; Guru, SA; Koner, BC; Mir, R; Saxena, A; Sumi, MP | 1 |
Alonso, RA; Ayala, R; Calbacho, M; Carreño-Tarragona, G; Colmenares, R; Cruz-Rojo, J; de la Cruz, J; García-Barrio, N; Gil, R; Gil-Alos, D; Hernández, G; Lopez, N; Martínez-López, J; Meloni, L; Pedrera-Jiménez, M; Pérez-Rey, D; Sánchez-Pina, J; Sanz, A; Serrano-Balazote, P | 1 |
Fabarius, A; Haferlach, C; Hehlmann, R; Hochhaus, A; Lauseker, M; Saußele, S; Voskanyan, A | 1 |
Jurajda, M; Knight, A; Mayer, J; Piskacek, M; Prochazkova, J; Racil, Z; Zackova, D | 1 |
Brewinska-Olchowik, M; Dudka, W; Hoser, G; Klejman, A; Kominek, A; Kusio-Kobialka, M; Machnicki, MM; Mondal, SS; Piwocka, K; Seferynska, I; Stoklosa, T; Swatler, J; Turos-Korgul, L; Wiech, M; Wołczyk, M | 1 |
Eşkazan, AE | 1 |
Chen, Y; Cheng, F; Cui, Z; Li, Q; Li, W; Zeng, F; Zhang, Y | 1 |
Prasad, V; Walia, A | 1 |
Ballarò, D; Buffolino, S; Lapietra, G; Limongi, MZ; Mancini, M; Martelli, M; Nanni, M | 1 |
Ross, DM | 1 |
Gale, RP; Huang, J; Huang, X; Jiang, Q; Liu, B; Qi, F; Zhang, X | 1 |
Branford, S; Dang, P; Hughes, TP; Kok, CH; Saunders, VA; Shanmuganathan, N; White, D; Yeung, D | 1 |
Bidet, A; Caillot, D; Chollet, C; Delmer, A; Dulucq, S; Gardembas, M; Genet, P; Lippert, E; Mahon, FX; Nicolini, FE | 1 |
Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K | 1 |
Ankathil, R; Azlan, H; Baba, AA; Elias, MH | 1 |
Hawes, V; Lobo, RH; Sasapu, A; Socola, F | 1 |
Bilgiş Gazioğlu, S; Birman, H; Candöken, E; Danışman Kalındemirtaş, F; Kuruca, S; Melikoğlu, G | 1 |
Cross, NC; Fabarius, A; Gosenca, D; Haferlach, C; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Schwaab, J | 1 |
Audureau, E; Garcia-Gonzalez, P; Ladner, J; Saba, J; Tavolacci, MP; Tekinturhan, E | 1 |
Aguiar, RC; Apperley, JF; Burbury, K; Cheah, CY; Cross, NC; Dunbar, CE; Forrest, D; Gardembas, M; Genet, P; Gimelfarb, A; Huguet, F; Ito, S; Odenike, O; Patton, N; Pitini, V; Ross, DM; Rousselot, P; Seymour, JF; Smith, G | 1 |
Clare-Salzler, MJ; Li, S; Xia, CQ; Xia, T; Xie, C; Yuan, L; Zhang, P | 1 |
Passamonti, F | 1 |
Endo, F; Jono, H; Kouroki, M; Ohmura, T; Saito, H; Taguchi, K | 1 |
Ahn, KS; Cho, JH; Chung, WS; Kim, C; Kim, MB; Kim, SH; Nam, D | 1 |
Bogdanovic, A; Elezovic, I; Gotic, M; Jankovic, G; Lekovic, D; Perunicic-Jovanovic, M | 1 |
Gupta, S; Kumar, H; Raj, U; Srivastava, S; Varadwaj, PK | 1 |
Adachi, S; Horibe, K; Hotta, N; Ishii, E; Ito, M; Kajiwara, R; Kurosawa, H; Mizutani, S; Moriya Saito, A; Muramatsu, H; Okada, M; Shima, H; Shimada, H; Tanizawa, A; Tono, C; Watanabe, A; Yuza, Y | 1 |
Hongeng, S; Ratanachamnong, P; Slukvin, I; Srihirun, S; Suknuntha, K; Thita, T; Togarrati, PP; Wongtrakoongate, P | 1 |
Bousema, MT; Hayes, DP; Kardaun, SH; Kramer, MH; Timmer-de Mik, L | 1 |
Berretta, S; Chiarenza, A; Conticello, C; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Stagno, F; Tibullo, D | 1 |
Albitar, M; Bornmann, W; Estrov, Z; Faderl, S; Harris, D; Hazan-Halevy, I; Kantarjian, HM; Liu, Z; Maxwell, D; Pal, A; Peng, Z; Van, Q | 1 |
Chan, AL; Hsieh, HJ; Lin, SJ | 1 |
Breitscheidel, L | 1 |
Abuav, R; Goldenberg, G; High, W; Pass, C; Skupsky, H | 1 |
Tojo, A | 1 |
Kiyokawa, N; Kiyotani, C; Mori, T | 1 |
Demetri, GD; Ganjoo, KN; Jacobs, C; Patel, S | 1 |
Bergua, A; Chankiewitz, E; Mackensen, A; Scholz, GA; Spriewald, BM | 1 |
Crawford, M; Dollins, CM; Grant, S; Graves, LM; Hammond, SM; Nana-Sinkam, SP; Richards, KL; Zimmerman, EI | 1 |
Feng, YQ; Li, X; Liu, J; Lü, S; Luo, Q; Wang, F; Wu, J; Xiong, S | 1 |
Chu, DT | 1 |
Hoffman, R; Kiladjian, JJ; Mesa, RA | 1 |
Eskander, RN; Herbst, KD; Kelly, TF; Tarsa, M | 1 |
Chang, CS; Hsu, CN; Lin, MT; Yang, YH | 1 |
Sawyers, CL | 1 |
Jedrzejczak, WW; Nurzyńska, D | 1 |
Frassoni, F; Luzzatto, L; Melo, JV | 1 |
Asaka, M; Hirabayashi, T; Hori, K; Kajimoto, S; Kondo, T; Masuda, Y; Nakajo, S; Nakaya, K; Nishida, A | 1 |
Almenara, J; Conrad, D; Dent, P; Grant, S; Krystal, G; Rahmani, M; Subler, M; Varticovski, L; Yu, C | 1 |
Griffin, JD; Sattler, M; Scheijen, B; Weisberg, E | 1 |
Ball, G; Beran, M; Cortes-Franco, JE; Divoky, V; Gatto, S; Kantarjian, HM; Keating, MJ; Milella, M; Onida, F; Pham, L; Ricci, C; Scappini, B; Verstovsek, S | 1 |
Nakajima, A; Ohyashiki, K; Sashida, G; Shimamoto, T; Sumi, M; Tauchi, T | 1 |
Hishita, T; Ichiyama, S; Miura, Y; Mizutani, C; Nishihara, T; Tohyama, K; Tohyama, Y; Uchiyama, T | 1 |
Beck, J; Breitenbuecher, F; Duyster, J; Fischer, T; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A; Peschel, C; Theobald, M; Weinkauf, B | 1 |
Krystal, GW | 1 |
Becton, DL; Chang, MN; Dahl, GV; Douglas, L; Kinnunen, P; Lacayo, NJ; Meshinchi, S; Radich, JP; Ravindranath, Y; Sikic, BI; Stuber, CM; Tibshirani, R; Wahab, R; Wang, Y; Weinstein, H; Willman, CL; Yu, R | 1 |
Anderson, K; Atadja, P; Catley, L; Cavazza, C; Fuerst, P; Griffin, JD; Kujawa, J; Remiszewski, S; Weisberg, E | 1 |
Annavarapu, S; Atadja, P; Bali, P; Bhalla, K; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Sondarva, G | 1 |
Advani, AS | 1 |
Amabile, M; Arpinati, M; Baccarani, M; Basi, C; Bocchia, M; Candoni, A; Cilloni, D; Fanin, R; Gaitani, S; Gottardi, E; Lauria, F; Maderna, M; Malagola, M; Marrè, MC; Martinelli, G; Ottaviani, E; Paolini, S; Piccaluga, PP; Rancati, F; Rondoni, M; Russo, D; Saglio, G; Vinaccia, V; Visani, G | 1 |
Bullorsky, E; Ricchione, D; Saxton, R; Schamun, A; Stemmelin, G | 1 |
Creutzig, U; Goemans, BF; Hählen, K; Harlow, A; Heinrich, MC; Kaspers, GJ; Loonen, AH; Meshinchi, S; Miller, M; Reinhardt, D; Zimmermann, M; Zwaan, CM | 1 |
Grever, MR | 1 |
Han, HY; Han, JY; Jeong, JS; Kim, HJ; Kwak, JY; Kwon, HC; Park, JI; Park, TH; Seo, C | 1 |
Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
Dumur, CI; Ferreira-Gonzalez, A; Fossey, SC; Garrett, CT; Vnencak-Jones, CL | 1 |
Ikeda, A; Moore, TB; Sakamoto, KM; Shankar, DB; Tamanoi, F; Watanabe, M | 1 |
Fladmark, KE; Gjertsen, BT; Hovland, R; Oveland, E; Wergeland, L | 1 |
Corbacioglu, S; Debatin, KM; Fulda, S; Kilic, M; Reinhardt, D; Westhoff, MA | 1 |
Chan, LC; Liu, HS; So, CC; Wan, TS; Wong, ML; Yip, SF | 1 |
Sell, S | 1 |
Bardini, M; Blasi, F; Calabretta, B; Corradini, F; Ferrari-Amorotti, G; Iotti, G; Lidonnici, MR; Martinez, R; Ronchetti, M; Rosafio, C; Zhang, Y | 1 |
Campiani, G; Greene, LM; Kelly, L; Lawler, M; Onnis, V; Williams, DC; Zisterer, DM | 1 |
Aulitzky, W; Cortes, J; Döhner, H; Fischer, T; Heidel, F; Huber, C; Kantarjian, H; Kindler, T; Letvak, L; Rücker, FG | 1 |
Aulitzky, WE; Beneke, H; Cross, NC; Del Valle, F; Diecker, F; Döhner, H; Erben, P; Haferlach, C; Haferlach, T; Hehlmann, R; Hochhaus, A; Hodges, E; Metzgeroth, G; Mix, J; Müller, L; Müller, MC; Müller-Hermelink, K; Popp, H; Reiter, A; Schmitz, N; Schnittger, S; Schuld, P; Schulte, C; Score, J; Siebert, R; Walz, C; Whittaker, SJ; Wittkowsky, G | 1 |
Bona, R; Kaplan, AA; Shafique, S | 1 |
Apperley, JF; Chaidos, A; Kanfer, E | 1 |
Clark, RE; Giannoudis, A; Lane, S; Pirmohamed, M; Wang, L; Williamson, P | 1 |
Antoniadis, A; Kalala, F; Kokoviadou, K; Korantzis, I; Plastiras, D; Speletas, M; Vyzantiadis, TA | 1 |
Ates, H; Pehlivan, M; Sercan, HO; Sercan, Z; Simsek, O | 1 |
Craddock, C | 1 |
Belotti, D; Bertazzoli, C; Biondi, A; Corneo, GM; Di Nicola, M; Fanelli, M; Gambacorti-Passerini, C; le Coutre, P; Lydon, NB; Marchesi, E; Mologni, L; Pogliani, E | 1 |
Dan, S; Kizaki, A; Mashima, T; Naito, M; Seimiya, H; Tsuruo, T | 1 |
Brown, E; Lewis, PH; Nocera, J | 1 |
Pestell, K | 1 |
Casadevall, N; Delmer, A; Legrand, O; Marie, JP; Rio, B; Ugo, V | 1 |
Bown, N; Capdeville, R; Chang, J; Connors, S; Melo, JV; O'Brien, SG; Vieira, SA | 1 |
Reviews
17 review(s) available for imatinib mesylate and Granulocytic Leukemia
Article | Year |
---|---|
Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature.
Topics: Antineoplastic Agents; Biomarkers; Bone Marrow; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Tumor Lysis Syndrome | 2018 |
[Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
[Clinical problems in the treatment of myeloid leukemia in childhood].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Communicable Diseases; Down Syndrome; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk | 2009 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine | 2010 |
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential | 2011 |
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Cell Surface | 2002 |
[Oncogene products inhibitors in the treatment of cancer].
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myeloid; Oncogene Proteins; Oncogenes; Piperazines; Pyrimidines | 2002 |
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Topics: Animals; Benzamides; Binding Sites; Clinical Trials as Topic; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myeloid; Mice; Mutation; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; src Homology Domains | 2003 |
Imatinib mesylate (STI571) for myeloid malignancies other than CML.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mastocytosis, Systemic; Myeloproliferative Disorders; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines | 2004 |
C-kit as a target in the treatment of acute myelogenous leukemia.
Topics: Acute Disease; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Hematopoiesis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Piperazines; Propionates; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor | 2005 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Thionucleotides | 2003 |
Molecular targets and the treatment of myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; ras Proteins; Receptor Protein-Tyrosine Kinases; Translocation, Genetic; Tretinoin | 2006 |
Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Signal Transduction | 2006 |
Leukemia: stem cells, maturation arrest, and differentiation therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myeloid; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2005 |
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous | 2007 |
Molecularly targeted therapy in myeloid leukaemias.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2007 |
[Update on malignant hemopathies].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotoxins; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Lymphoma; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Tretinoin | 2002 |
Trials
5 trial(s) available for imatinib mesylate and Granulocytic Leukemia
Article | Year |
---|---|
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Count; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myeloid; Male; Middle Aged; Phosphorylation; Pilot Projects; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Treatment Outcome | 2004 |
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Stem Cell Factor; Survival Rate; Treatment Outcome | 2007 |
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Topics: Acute Disease; Adult; Aged; Benzamides; Disease-Free Survival; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Nucleophosmin; Oncogene Proteins, Fusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction | 2007 |
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line, Tumor; Disease-Free Survival; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myeloid; Middle Aged; Mutation; Neoplasm Proteins; Octamer Transcription Factor-1; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Regression Analysis; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Treatment Outcome | 2008 |
Other Studies
67 other study(ies) available for imatinib mesylate and Granulocytic Leukemia
Article | Year |
---|---|
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors.
Topics: Animals; Antineoplastic Agents; Chronic Disease; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Interleukin-1 Receptor-Associated Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Mice; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors | 2022 |
Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
Topics: Apoptosis; Cell Cycle; Chronic Disease; Cytokines; Disease Progression; DNA; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Surveys and Questionnaires; Tumor Suppressor Protein p14ARF | 2022 |
Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2022 |
Impact of emerging ACA on survival in chronic myeloid leukemia (CML).
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2022 |
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Topics: Cell Line; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets | 2023 |
Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells.
Topics: Animals; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mice; Protein Kinase Inhibitors; Signal Transduction; STAT5 Transcription Factor | 2022 |
Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Treatment Outcome | 2023 |
Reply to "Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!"
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2023 |
Is it time to reconsider molecular response milestones in chronic myeloid leukemia?
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Protein Kinase Inhibitors | 2023 |
Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.
Topics: Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Polycythemia Vera | 2023 |
Single cells tell multiple tales in CML.
Topics: Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2023 |
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2023 |
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.
Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Splenomegaly | 2023 |
Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.
Topics: Adult; Aged; Antineoplastic Agents; Gene Rearrangement; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Oncogene Proteins, Fusion; Real-Time Polymerase Chain Reaction | 2018 |
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients.
Topics: Chronic Disease; DNA Methylation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid; Promoter Regions, Genetic; Suppressor of Cytokine Signaling 1 Protein | 2018 |
Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method
Topics: Antineoplastic Agents; Cytotoxins; Data Analysis; Flavonoids; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid | 2019 |
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Eosinophilia; Follow-Up Studies; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lymphoma, T-Cell; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Myeloid; Survival Rate | 2013 |
Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.
Topics: Antineoplastic Agents; Benzamides; Developing Countries; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Health Services Accessibility; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Quality Improvement; Survival | 2013 |
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Eosinophilia; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid; Male; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic; Young Adult | 2014 |
C-Abl inhibitor imatinib enhances insulin production by β cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
Topics: Animals; Benzamides; Cell Line; Gene Expression Regulation; Glucose; Glucose Transporter Type 2; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Imatinib Mesylate; Insulin; Insulin-Secreting Cells; Leukemia, Myeloid; Mice; Peptide Biosynthesis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; RNA, Small Interfering; Trans-Activators; Transcription Factors; Zebrafish Proteins | 2014 |
PDGFRB disease: right diagnosis to prolong survival.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2014 |
Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia.
Topics: Anticonvulsants; Carbamazepine; Child; Drug Interactions; Epilepsy; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Protein Kinase Inhibitors | 2014 |
The hydrolysed products of iridoid glycosides can enhance imatinib mesylate-induced apoptosis in human myeloid leukaemia cells.
Topics: Apoptosis; Benzamides; Caspase 3; Cell Proliferation; CSK Tyrosine-Protein Kinase; Down-Regulation; Humans; Imatinib Mesylate; Iridoid Glucosides; Iridoid Glycosides; Janus Kinase 2; K562 Cells; Leukemia, Myeloid; Phosphorylation; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor | 2015 |
Diagnostic challenges during pretreatment long-term follow-up in a patient with FIP1L1-PDGFRA-positive eosinophilia.
Topics: Adult; Antineoplastic Agents; Benzamides; Eosinophilia; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome | 2015 |
Identification of Dual Natural Inhibitors for Chronic Myeloid Leukemia by Virtual Screening, Molecular Dynamics Simulation and ADMET Analysis.
Topics: Animals; Antineoplastic Agents; Computational Biology; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myeloid; Molecular Dynamics Simulation | 2016 |
Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myeloid; Leukostasis; Male; Retrospective Studies; Young Adult | 2016 |
Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia, Myeloid; Leukocytes, Mononuclear; Receptor Cross-Talk; Sulfonamides; Wnt Signaling Pathway | 2017 |
Imatinib-induced pseudoporphyria.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytarabine; Drug Eruptions; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Piperazines; Porphyrias; Pyrimidines | 2009 |
Effects of imatinib mesylate in osteoblastogenesis.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mesenchymal Stem Cells; Molecular Sequence Data; Osteoblasts; Osteogenesis; Piperazines; Pyrimidines; Reference Standards; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Benzamides; Caspases; Cell Growth Processes; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mutation; Oncogene Protein v-akt; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyridines; Pyrimidines; STAT3 Transcription Factor; Stem Cell Factor; Thiazoles | 2009 |
Stevens-Johnson syndrome induced by combination of imatinib and allopurinol.
Topics: Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Female; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Leukemia, Myeloid; Piperazines; Pyrimidines; Stevens-Johnson Syndrome | 2009 |
Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Cost-Benefit Analysis; Germany; Humans; Imatinib Mesylate; Leukemia, Myeloid; Markov Chains; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2008 |
Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lichen Sclerosus et Atrophicus; Piperazines; Pyrimidines | 2010 |
Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.
Topics: Acute Disease; Aged; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
[Fundus leucaemicus as first manifestation of chronic myeloid leukemia. Diagnosis and monitoring with OCT under treatment with imatinib and interferon-alpha].
Topics: Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid; Male; Piperazines; Pyrimidines; Retinal Diseases; Tomography, Optical Coherence; Treatment Outcome; Young Adult | 2010 |
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Calcitriol; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; src-Family Kinases | 2010 |
Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO2 nanoparticle deposited capillary column.
Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myeloid; Nanoparticles; Phosphopeptides; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Titanium | 2010 |
Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukapheresis; Leukemia, Myeloid; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Remission Induction; Treatment Outcome | 2011 |
Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis.
Topics: Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Female; Guideline Adherence; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid; Longitudinal Studies; Male; Middle Aged; Piperazines; Pyrimidines; Taiwan | 2012 |
Imatinib: can one outwit chronic myeloid leukemia?
Topics: Benzamides; Enzyme Inhibitors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Line; Cysteine Proteinase Inhibitors; DNA, Complementary; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genistein; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Kidney; Leukemia, Myeloid; Naphthoquinones; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; U937 Cells | 2003 |
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Mitochondria; Piperazines; Pyrimidines; Signal Transduction; U937 Cells; Vorinostat | 2003 |
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Topics: Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myeloid; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Proteasome Endopeptidase Complex; Pyrazines; Pyrimidines | 2003 |
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Mice; Mice, Nude; Oligonucleotides, Antisense; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Survival Analysis; Thionucleotides; Time Factors; Transplantation, Heterologous | 2003 |
Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
Topics: Benzamides; Cell Adhesion; Cell Division; Cell Line, Tumor; Cell Size; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Milk Proteins; Oncogene Protein v-cbl; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-crk; Pyrimidines; Retroviridae Proteins, Oncogenic; STAT5 Transcription Factor; Trans-Activators; Transfection | 2003 |
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
Topics: Acute Disease; Adolescent; Adult; Benzamides; Child; Child, Preschool; Cluster Analysis; Core Binding Factor Alpha 3 Subunit; Disease-Free Survival; DNA Helicases; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid; Mutation; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Transcription Factors; X-linked Nuclear Protein | 2004 |
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Topics: Acetylation; Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Marrow Cells; Cell Cycle; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Phosphorylation; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tyrosine | 2004 |
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Topics: Acute Disease; Apoptosis; Benzamides; Benzoquinones; Blast Crisis; Cell Line, Tumor; Drug Combinations; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Gene Deletion; Gene Expression Regulation; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Panobinostat; Piperazines; Point Mutation; Polyubiquitin; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Rifabutin | 2005 |
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Treatment with cyclosporin A cream for the cutaneous reactions associated with imatinib therapy.
Topics: Administration, Topical; Antineoplastic Agents; Benzamides; Cyclosporine; Drug Hypersensitivity; Female; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Piperazines; Pyrimidines | 2005 |
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; CHO Cells; Core Binding Factors; Cricetinae; Cytogenetic Analysis; Exons; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Genes, ras; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myeloid; Mutation; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Transcription Factors; Treatment Outcome | 2005 |
Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells.
Topics: Amino Acid Sequence; Base Sequence; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Molecular Sequence Data; Mutagenesis, Insertional; Nucleotides; Piperazines; Point Mutation; Pyrimidines | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity | 2005 |
Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.
Topics: Acute Disease; Adolescent; Animals; Benzamides; Cell Line; Cell Proliferation; Child; Child, Preschool; DNA, Neoplasm; Drug Synergism; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid; Male; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Cross-Talk; Sirolimus; STAT Transcription Factors; Tandem Repeat Sequences; Transfection | 2006 |
Philadelphia chromosome unmasked as a secondary genetic change in acute myeloid leukemia on imatinib treatment.
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines | 2006 |
Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
Topics: Animals; Benzamides; Bone Marrow Cells; Carcinogenicity Tests; CCAAT-Enhancer-Binding Protein-alpha; Cell Proliferation; Chemokines, CC; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Imatinib Mesylate; Leukemia, Myeloid; Macrophage Inflammatory Proteins; Mice; Mice, Inbred C3H; Mice, SCID; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Repressor Proteins; Tumor Cells, Cultured | 2007 |
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Topics: Apoptosis; bcl-X Protein; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Microtubules; Monocytes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxazepines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles | 2007 |
Gleevec may be heart toxic.
Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Pyrimidines | 2007 |
A case report of therapeutic leukapheresis in an adult with chronic myelogenous leukemia presenting with hyperleukocytosis and leukostasis.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Viscosity; Chronic Disease; Humans; Imatinib Mesylate; Leukapheresis; Leukemia, Myeloid; Leukocytosis; Leukostasis; Male; Piperazines; Pyrimidines; Retinal Hemorrhage | 2007 |
Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment.
Topics: Aged; Benzamides; Candida; Candidiasis; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lung; Male; Opportunistic Infections; Piperazines; Pneumonia; Polymorphism, Genetic; Pyrimidines; Radiography; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2008 |
Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin D1; Etoposide; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Wnt Proteins | 2007 |
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
Topics: Apoptosis; Benzamides; Cell Differentiation; Cell Division; Cell Line; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 1997 |
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
Topics: Apoptosis; Aspartic Acid; Benzamides; Calcium-Calmodulin-Dependent Protein Kinases; Caspase Inhibitors; Caspases; Enzyme Activation; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; U937 Cells | 1999 |
In search of the silver bullet.
Topics: Antineoplastic Agents; Benzamides; Computers; Creativity; Entrepreneurship; Environmental Pollution; Humans; Imatinib Mesylate; Internet; Leukemia, Myeloid; Piperazines; Pyrimidines; Research; Technology; United States; Vaccines | 2001 |
Anti-cancer drug success emerges from molecular biology origins.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Molecular Biology; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Topics: Acute Disease; Adult; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 9; DNA-Binding Proteins; ETS Translocation Variant 6 Protein; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-ets; Pyrimidines; Recurrence; Repressor Proteins; Translocation, Genetic | 2002 |